Preclinical drug development and CRO with focus on autoimmunity | Redoxis

Redoxis focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS).